New Recall on Diabetes Drug
A popular diabetes drug, metformin hydrochloride extended-release tablets, which is used to treat type 2 diabetes and is designed to lower glucose levels, has been recalled after manufacturers found that it contained unacceptably high levels of a cancer-causing contaminant. The pharmaceutical company that produces the drug, Marksans Pharma Limited, found that their levels of NDMA, a “probable human carcinogen,” were higher than the acceptable daily intake limit of 96 nanograms per day, causing them to issue the recall. The recall includes any metformin tablets between 500 mg and 750 mg that are sold under the brand name Time-Cap Labs, Inc.
This recall expands on an earlier recall of the same product from a few months prior. This is not the only metformin product that has been found to contain NDMA in the last year. In total, there have been Seven other pharmaceutical companies that have had to issue recalls for metformin hydrochloride extended-release tablets due to their carcinogenic contents.
The recall applies to the below products, which can be identified by their National Drug Code numbers. The tablets are either embossed with 101 or 102 on one side and are plain on the other.
Metformin Hydrochloride Extended-Release Tablets, USP 500mg:
- 90 counts: 49483-623-09
- 100 counts: 49483-623-01
- 500 counts: 49483-623-50
- 1000 counts: 49483-623-10
Metformin Hydrochloride Extended-Release Tablets, USP 750mg:
- 100 counts: 49483-624-01
If you have been taking metformin hydrochloride extended-release tablets, it is advised that you consult with your doctor before continuing use.